Danish CNS drug specialist Lundbeck (LUND: CO) has reported revenues of 11.67 billion Danish kroner ($2.11 billion) for the first nine months of 2013, up 7% from 10.96 billion kroner in the same period in 2012, with new product sales rising 41%. The stock rose 4.3% to 126.50 kroner by mid afternoon trading on November 6.
Profit from operations (EBIT) grew by 7% to 1.53 billion kroner during the first nine months, corresponding to an EBIT margin of 13%. In the third quarter Lundbeck recognized the remaining divestiture gain to Italian drugmaker Recordati (RC: MI) of 112 million kroner and the provision related to the Fit-for-the-Future program of 200 million kroner. Earnings per share (and diluted earnings per share) were 1.36 kroner, down from 2.17 kroner in the like 2012 period.
Lundbeck´s president and chief executive Ulf Wiinberg said: “This has been yet another strong period for Lundbeck – from a financial, regulatory and clinical development perspective. With the most recent FDA approval of Brintellix we have achieved a solid platform for our ambition to provide long-term growth”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze